Bethesda, Maryland, August 5, 2026
The National Institutes of Health (NIH), through the National Cancer Institute (NCI) and its international Human Cancer Models Initiative (HCMI), has unveiled one of the world’s most comprehensive collections of patient-derived human cancer models, providing researchers with a transformative resource to accelerate precision oncology, therapeutic discovery, and translational cancer research. Published in Nature, the decade-long initiative has established a catalog of 665 next-generation laboratory models representing 25 different tumor types derived from 2,780 patient donors. The collection captures the genetic diversity of human cancers while preserving critical molecular characteristics of the original tumors, creating an unprecedented platform for studying tumor biology, treatment resistance, biomarker discovery, and personalized cancer therapies. The internationally accessible repository is expected to strengthen collaboration across academia, biotechnology, and pharmaceutical research while supporting the development of next-generation cancer treatments tailored to individual patients.
Comprehensive Patient-Derived Cancer Models Advance Research
The Human Cancer Models Initiative (HCMI) was created to overcome limitations associated with traditional laboratory cancer models that often fail to reflect the biological complexity of human tumors. Researchers developed 665 highly characterized patient-derived models encompassing 25 major cancer types, including many common cancer subtypes and key genetic alterations observed in clinical practice. These laboratory-grown models include advanced tumor organoids, cell cultures, and neurosphere models that closely replicate the cellular composition, genetic architecture, and biological behavior of their parental tumors. Extensive molecular analyses demonstrated remarkable fidelity between original patient tumors and corresponding laboratory models, with 97.8% agreement in genetic alterations, 95% concordance in epigenetic features, and 92% similarity in RNA expression profiles. These findings confirm that the models preserve essential biological characteristics even after prolonged laboratory growth, making them valuable tools for investigating cancer progression, disease mechanisms, and therapeutic responses.
Precision Oncology and Drug Development Receive Major Boost
One of the most significant advantages of the new HCMI resource is its potential to accelerate precision oncology and improve preclinical drug development. Scientists can now investigate how specific genetic mutations influence treatment response while identifying biomarkers associated with therapeutic resistance and disease progression. The collection enables researchers to correlate genomic characteristics with sensitivity to targeted therapies, immunotherapies, and emerging anticancer drugs. In glioblastoma, for example, investigators identified genetic alterations linked to resistance against temozolomide, providing valuable insights into why some patients experience disease recurrence despite treatment. Because the patient-derived models closely resemble the original tumors, researchers expect they will improve the identification of novel therapeutic vulnerabilities and facilitate the development of more personalized treatment strategies. The availability of comprehensive genomic, transcriptomic, epigenomic, and clinical datasets alongside each model further strengthens opportunities for biomarker discovery and translational research.
Advertisement
Global Resource Supports Future Cancer Innovation
Beyond its scientific significance, the HCMI repository represents an important international infrastructure supporting future cancer research. The collection includes 522 models accompanied by detailed clinical information, 153 rare cancer models, and 71 models derived from individuals of non-European ancestry, significantly expanding representation across diverse patient populations. Through collaboration with the American Type Culture Collection (ATCC), these models are being made broadly available to researchers worldwide, enabling standardized investigations into tumor biology, therapeutic resistance, and next-generation treatment development. Published alongside complementary studies from leading international research institutions, the initiative establishes a robust scientific foundation for future discoveries in precision medicine, drug development, and translational oncology. By providing access to highly validated human cancer models, NIH and NCI are equipping researchers with critical tools that could accelerate the development of safer, more effective, and highly personalized therapies for patients facing a broad spectrum of cancers.
Source: NIH press release
